Despite the small proportion of patients with metastatic disease who were recruited in this study, many urologists selected CAB rather than GnRH agonist monotherapy for treatment, which resulted in failure to recruit sufficient subjects in the GnRH group. Here, GNRH1 is linked to metastatic neoplasm.